SCHEMBL3720947 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	NR3C1	P04150	6/20	0.35

▸	TYK2	P29597	1/20	0.35

▸	JAK2	O60674	1/20	0.35

▸	JAK1	P23458	1/20	0.35

▸	MEN1	O00255	2/20	0.34

▸	LMNA	P02545	2/20	0.34

▸	HPGD	P15428	2/20	0.34

▸	KMT2A	Q03164	2/20	0.34

▸	ALDH1A1	P00352	1/20	0.34

▸	MAPT	P10636	1/20	0.34

▸	HIF1A	Q16665	1/20	0.34

▸	MALT1	Q9UDY8	2/20	0.34

▸	CCR5	P51681	2/20	0.34

▸	RAB9A	P51151	1/20	0.34

▸	UBE2M	P61081	1/20	0.34

▸	DCUN1D1	Q96GG9	1/20	0.34

▸	KDM4E	B2RXH2	1/20	0.33

▸	NPC1	O15118	1/20	0.33

▸	TSHR	P16473	1/20	0.33

▸	SMN1; SMN2	Q16637	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL3723311	0.93	MALT1 (0.37)	NR3C1TYK2MEN1LMNAHPGD
SCHEMBL13013388	0.86	CCNE1 (0.38)	TYK2JAK2JAK1
SCHEMBL3722340	0.86	CCNE1 (0.38)	TYK2JAK2JAK1
SCHEMBL3722334	0.86	CCNE1 (0.38)	TYK2JAK2JAK1
SCHEMBL3719962	0.86	NOD2 (0.37)	LMNACCR5UBE2MDCUN1D1
SCHEMBL3725541	0.84	FAAH (0.37)	CCR5UBE2MDCUN1D1SMN1; SMN2
SCHEMBL3664306	0.84	MAPT (0.38)	NR3C1MEN1LMNAHPGDKMT2A
SCHEMBL20504495	0.82	PDE1B (0.38)	TYK2MEN1KMT2ACCR5UBE2M
SCHEMBL3667219	0.82	FYN (0.37)	TYK2LMNAHIF1AMALT1RAB9A
SCHEMBL3722488	0.82	CCNE1 (0.38)	TYK2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-2240488-B1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	BRISTOL MYERS SQUIBB CO (US)	2016-11-02	—	—	EP	disclosed
EP-2240488-B1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	BRISTOL MYERS SQUIBB CO (US)	2016-11-02	—	—	EP	disclosed
US-8389527-B2	Substituted imidazopyridazines useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2013-03-05	—	—	US	disclosed
US-8389527-B2	Substituted imidazopyridazines useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2013-03-05	—	—	US	disclosed
US-8389527-B2	Substituted imidazopyridazines useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2013-03-05	—	—	US	disclosed
US-20100323994-A1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2010-12-23	—	—	US	disclosed
US-20100323994-A1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2010-12-23	—	—	US	disclosed
US-20100323994-A1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2010-12-23	—	—	US	disclosed
EP-2240488-A1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	Bristol-Myers Squibb Company (US)	2010-10-20	—	—	EP	disclosed
WO-2009100375-A1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2009-08-13	—	—	WO	disclosed
WO-2009100375-A1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2009-08-13	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100323994-A1	SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS	MAP3K5, MAP4K2, MAP3K15	NR3C1 3628/4885TYK2 289/4885JAK2 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.